A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 825-834

  Rodon, Jordi ^a,d   Jacobs, Charlotte D ^b   Chu, Quincy ^a,e   Rowinsky, Eric K ^a,f   Lopez Anaya, Arturo ^c,g   Takimoto, Chris H ^a,h   Wakelee, Heather A ^b  

^a CTRC Institute for Drug Development   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EISAI INC   (United States)

^d VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^e UNIVERSITY OF ALBERTA   (Canada)

^f Oncodrugs Consulting   (United States)

^g Forest Laboratories Inc   (United States)

^h JOHNSON AND JOHNSON   (United States)

Author keywords

Bexarotene; Carboplatin; Paclitaxel; Pharmacokinetics; Phase I

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BEXAROTENE; BILIRUBIN; CARBOPLATIN; CREATININE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; FENOFIBRATE; ONDANSETRON; PACLITAXEL; RETINOL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KIDNEY FUNCTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES;

EID: 84859762438     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1770-1     Document Type: Article

References (40)

1. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1(3):181-193 (Pubitemid 33741893)
2. Sun SY, Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41(1):41-55
3. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337(15):1021-1028 (Pubitemid 27430519)
4. Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P (2006) Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 24(36):5703-5710 (Pubitemid 46631312)
5. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94(4): 1192-1200 (Pubitemid 29380399)
6. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D et al (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 82(11):3241-3249
7. Prince HM, McCormack C, Ryan G, Baker C, Rotstein H, Davison J, Yocum R (2001) Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australas J Dermatol 42(2):91-97 (Pubitemid 32436760)
8. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137(5):581-593 (Pubitemid 32458440)
9. Soignet SL, Miller VA, Pfister DG, Bienvenu BJ, Ho R, Parker BA, Amyotte SA, Cato A III, Warrell RP Jr (2000) Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550). Clin Cancer Res 6(5):1731-1735 (Pubitemid 30305065)
10. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, Hawkins MJ (1999) A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5(7):1658-1664 (Pubitemid 29334442)
11. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell RP Jr (1997) Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15(2):790-795 (Pubitemid 27074250)
12. Rigas JR, Dragnev KH (2005) Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 10(1): 22-33 (Pubitemid 40171249)
13. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E (1997) Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 94(22):12070-12074 (Pubitemid 27467844)
14. Song JI, Lango MN, Hwang JD, Drenning SD, Zeng Q, Lamph WW, Grandis JR (2001) Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res 61(15):5919-5925 (Pubitemid 32769112)
15. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E (1999) Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 274(31):22013-22018
16. Sah JF, Eckert RL, Chandraratna RA, Rorke EA (2002) Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation. J Biol Chem 277(12):9728-9735 (Pubitemid 34968074)
17. Yen WC, Lamph WW (2006) A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate 66(3):305-316
18. Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP (2005) The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 50(1):9-18 (Pubitemid 41297464)
19. Yen WC, Lamph WW (2005) The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 4(5):824-834
20. Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW (2004) A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin Cancer Res 10(24):8656-8664 (Pubitemid 40053434)
21. Yen WC, Prudente RY, Lamph WW (2004) Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat 88(2):141-148 (Pubitemid 39575571)
22. Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A (2008) Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 26(11):1879-1885
23. Fujino H, Yamada I, Shimada S, Hirano M, Tsunenari Y, Kojima J (2003) Interaction between fibrates and statins - metabolic interactions with gemfibrozil. Drug Metabol Drug Interact 19(3):161-176 (Pubitemid 37505160)
24. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68(2):122-129 (Pubitemid 30659167)
25. Calvert AH (1994) Dose optimisation of carboplatin in adults. Anticancer Res 14(6A):2273-2278
26. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92-98 (Pubitemid 34438899)
27. Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/ clinpharm/ddis/table.asp. Accessed 26 Jan 2010
28. Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling (2006) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), September 2006
29. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, Yang L (2009) Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39(4):283-292
30. Wakelee HA, Middleton G, Dunlop D, Ramlau R, Leighl N, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD (2011) A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced nonsmall-cell lung cancer (NSCLC). doi:10.1007/s00280-011-1771-0
31. Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE (2008) Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 26(11):1886-1892
32. Govindan R, Crowley J, Schwartzbberg L, Kennedy P, Ekstrand BC, Sandler A, Juanakais D, Ghalie R (2005) Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB/IV disease. J Clin Oncol 23(16s):648s Abstract #7116
33. Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E (2005) Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23(34):8757-8764 (Pubitemid 46211521)
34. Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R (2007) Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6(1):70-81 (Pubitemid 46206669)
35. Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC (2005) A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem 48(15):5047-5051 (Pubitemid 41033145)
36. Emionite L, Galmozzi F, Grattarola M, Boccardo F, Vergani L, Toma S (2004) Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. Anticancer Res 24(6):4019-4024 (Pubitemid 40468701)
37. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with alltrans retinoic acid. Cancer Res 61(9):3591-3594 (Pubitemid 32694967)
38. Lee SJ, Yang EK, Kim SG (2006) Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation. Mol Pharmacol 70(1):415-425
39. Murad H, Collet P, Huin-Schohn C, Al-Makdissy N, Kerjan G, Chedotal A, Donner M, Devignes MD, Becuwe P, Schohn H, Domenjoud L, Dauca M (2006) Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int J Oncol 28(4):977-984
40. Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF (2003) Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther 73(5):406-416 (Pubitemid 36549825)